Celgene Withdraws Drug Applications; Shares Fall 12%
Celgene shares tumbled early Thursday after the drugmaker said it's withdrawing its submission in Europe for a new indication for its drug Revlimid, which treats the blood cancer multiple myeloma. Celgene was seeking permission to use the drug to treat newly diagnosed multiple myeloma patients who have not progressed after initial treatments with some other drugs, or to serve as maintenance therapy following stem cell transplants. The company said
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here